CellSource Co., Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
CellSource Co., Ltd. owes ¥0.13 for every ¥1 it owns. Net profit fell 96% in the year to Oct 2025, and shrank 78% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Oct 2025.
P/E ratio
62.2Investors pay ¥62.2 for every ¥1 of CellSource Co., Ltd.'s yearly profit, higher than 92% of Healthcare companies in Japan.
P/B ratio
1.01The share price is 1.01 times CellSource Co., Ltd.'s book value per share, lower than 75% of Healthcare companies in Japan.
Market cap
¥6.1 BThe total market value of all of CellSource Co., Ltd.'s shares at today's price (share price × number of shares), smaller than 74% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥6.1 BWhat CellSource Co., Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Jul 2026).
Book value per share
¥305.65Net worth divided by the number of shares. The share price of ¥309.00 is 1.0 times this, which is the P/B above.
Owes vs Owns
0.13×CellSource Co., Ltd. owes ¥0.13 for every ¥1 it owns (low), lower than 88% of Healthcare companies in Japan.
Dividend yield
1.62%CellSource Co., Ltd. pays 1.62% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in Japan.
Revenue growth
-15%Revenue fell 15% in the year to Oct 2025, and shrank 5% a year on average over 3 years.
Profit growth
-96%Net profit fell 96% in the year to Oct 2025, and shrank 78% a year on average over 3 years.
Profit margin
0.3%CellSource Co., Ltd. keeps ¥0 of every ¥100 of revenue as net profit.
Cash quality
31.3×Cash from CellSource Co., Ltd.'s business was 31.3× its reported profit in the year to Oct 2025 — its profit turned into cash.
Interest cover
126.9×CellSource Co., Ltd.'s operating profit covered its interest costs 126.9 times in the year to Oct 2025.
Cash vs debt
Net cashCellSource Co., Ltd. held ¥4.7 B more cash than debt (net cash) at Oct 2025.
Questions
What is CellSource Co., Ltd.'s P/E ratio?
Investors pay ¥62.2 for every ¥1 of CellSource Co., Ltd.'s yearly profit, higher than 92% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For CellSource Co., Ltd.: ¥6.1 B ÷ ¥6.1 B (31 Jul 2026) = 1.0.
How much does CellSource Co., Ltd. owe compared with what it owns?
CellSource Co., Ltd. owes ¥0.13 for every ¥1 it owns (low), lower than 88% of Healthcare companies in Japan.
Does CellSource Co., Ltd. pay a dividend?
Yes. CellSource Co., Ltd. pays 1.62% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in Japan.
Is CellSource Co., Ltd.'s revenue growing?
Revenue fell 15% in the year to Oct 2025, and shrank 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.